RPG Life Sciences Limited (RPGLIFE) fundamentals
RPG Life Sciences Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as RPGLIFE (ISIN INE105J01010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What RPG Life Sciences Limited does
RPG Life Sciences Limited is an India-based research-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations, and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has a presence in nephrology, oncology, rheumatology, cardiology, respiratory, pain management, vitamins & minerals, gastroenterology, and gynecology & pediatrics. The International Formulations business operates in the generics and branded generics space across Canada, Europe, Australia, New Zealand, and South America. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Quinfamide, Nicorandil, Haloperidol, Risperidone, Tolvaptan, Spironolactone, Sertraline, Naprosyn, Teristrong, and others.
Valuation and market data
| Last close | ₹2698.60 |
|---|---|
| Market capitalisation | ₹4,463 crore |
| Enterprise value | ₹4,340 crore |
| P/E (TTM) | 38.75 |
| Price to book | 7.37 |
| Price to sales (TTM) | 3.49 |
| Book value per share | ₹366.04 |
| Dividend yield | 88.94% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Tue Jun 10 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹733 crore | ₹154 crore | ₹115 crore | 69.64 |
| Mar 2025 | ₹666 crore | ₹233 crore | ₹183 crore | 110.80 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 73.0% |
|---|---|
| Foreign institutions (FII) | 0.9% |
| Mutual funds | 0.0% |
| Other domestic institutions | 8.6% |
| Retail and others | 17.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.